Genetic Basis of Coronary Artery Disease: From GWAS Genome-Wide Association Studies to Precision Medicine

Coronary artery disease (CAD) remains the leading cause of morbidity and mortality worldwide and results from a complex interplay of genetic and environmental factors (1, 2). Although traditional risk factors such as hypertension, diabetes mellitus, and dyslipidemia are well established, genetic predisposition significantly contributes to disease susceptibility and progression (1, 12). Advances in genome-wide association studies (GWAS)have identified numerous loci associated with CAD, implicating pathways related to lipid metabolism, inflammation, and vascular remodeling (3,13,14). Epigenetic mechanisms and gene-environment interactions further modulate disease expression and contribute to phenotypic variability (9, 22).
Polygenic risk scores (PRS), which integrate the cumulative effects of multiple genetic variants, have emerged as valuable tools for risk prediction and early identification of high-risk individuals (10, 16). However, despite these advances, challenges related to clinical implementation, population diversity, and ethical considerations remain significant barriers to translation into routine practice ( 24, 28,29). This review provides a comprehensive and critical overview of the genetic architecture of CAD and highlights the translational potential and limitations of precision medicine approaches in cardiovascular care.

Coronary artery disease; genetics; GWAS Genome-Wide Association Studies; polygenic risk score; epigenetics; precision medicine

1. Khera AV, Kathiresan S. Genetics of coronary artery disease. Nat Rev Genet. 2017;18(6):331-344. [Google Scholar] [Crossref]

2. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive genome-wide association study of coronary artery disease. Nat Genet. 2015; 47(10):1121-1130. [Google Scholar] [Crossref]

3. Nelson CP, Goel A, Butterworth AS, Kanoni S, Webb TR, Marouli E, et al. Association analyses based on false discovery rate implicate new loci for coronary artery disease. Nat Genet. 2017; 49(9):1385-1391. [Google Scholar] [Crossref]

4. Goldstein JL, Brown MS. A century of cholesterol and coronaries: From plaques to genes to statins. Cell. 2015; 161(1):161-172. [Google Scholar] [Crossref]

5. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017; (18):1713-1722. [Google Scholar] [Crossref]

6. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868-874. [Google Scholar] [Crossref]

7. McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, et al. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007; 316(5830):1488-1491. [Google Scholar] [Crossref]

8. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing heritability of complex diseases. Nature. 2009; 461(7265):747-753. [Google Scholar] [Crossref]

9. Ordovás JM, Smith CE. Epigenetics and cardiovascular disease. Nat Rev Cardiol. 2010; 7(9):510-519. [Google Scholar] [Crossref]

10. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018; 50(9):1219-1224. [Google Scholar] [Crossref]

11. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome P450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360(4):354-362. [Google Scholar] [Crossref]

12. Kathiresan S, Srivastava D. Genetics of human cardiovascular disease. Cell. 2012; 148(6):1242-1257. [Google Scholar] [Crossref]

13. Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013; 45(1):25-33. [Google Scholar] [Crossref]

14. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011; 43(4):333-338. [Google Scholar] [Crossref]

15. Roberts R, Stewart AF. Genes and coronary artery disease: Where are we? J Am Coll Cardiol. 2012; 60(18):1715-1721. [Google Scholar] [Crossref]

16. Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat Rev Genet. 2018; 19(9):581-590. [Google Scholar] [Crossref]

17. Abraham G, Havulinna AS, Bhalala OG, Byars SG, De Livera AM, Yetukuri L, et al. Genomic prediction of coronary heart disease. Circulation. 2016; 133(24):1-9. [Google Scholar] [Crossref]

18. Inouye M, Abraham G, Nelson CP, Wood AM, Sweeting MJ, Dudbridge F, et al. Genomic risk prediction of coronary artery disease in 480,000 adults. J Am Coll Cardiol. 2018; 72(16):1883-1893. [Google Scholar] [Crossref]

19. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Eur Heart J. 2017; 38(32):2459-2472. [Google Scholar] [Crossref]

20. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017; 377(12):1119-1131. [Google Scholar] [Crossref]

21. Musunuru K, Kathiresan S. Genetics of common, complex coronary artery disease. Annu Rev Genomics Hum Genet. 2019; 20:1-21. [Google Scholar] [Crossref]

22. Emdin CA, Khera AV, Kathiresan S. Mendelian randomization. JAMA. 2017; 317(6):626-634. [Google Scholar] [Crossref]

23. Knowles JW, Ashley EA. Cardiovascular disease: The rise of the genetic risk score. PLoS Med. 2018; 15(3):e1002546. [Google Scholar] [Crossref]

24. Aragam KG, Dobbyn A, Judy R, Chaffin M, Chaudhary K, Hindy G, et al. Limitations of polygenic risk scores. Nat Genet. 2020; 52(6):550-558. [Google Scholar] [Crossref]

25. Levin MG, Rader DJ. Polygenic risk scores and coronary artery disease. Circulation. 2020; 141(8):637-640. [Google Scholar] [Crossref]

26. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet. 2019; 51(4):584-591. [Google Scholar] [Crossref]

27. Duncan L, Shen H, Gelaye B, Meijsen J, Ressler K, Feldman M, et al. Analysis of polygenic risk score usage. Nat Commun. 2019; 10: 3328. [Google Scholar] [Crossref]

28. Sirugo G, Williams SM, Tishkoff SA. The missing diversity in human genetic studies. Cell. 2019; 177(1):26-31. [Google Scholar] [Crossref]

29. Hindorff LA, Bonham VL, Ohno-Machado L. Enhancing diversity in genomics research. Nature. 2018;558(7710):301-303 [Google Scholar] [Crossref]

• Treasure of 6th Edition of Organon of Medicine- Lm Potency
• Neurobehavioral and Immune-Histochemical Effects of Daucus Carota Ethanolic Leaf Extract in Cadmium-Induced Toxicity of the Hippocampus and Prefrontal Cortex of Adult Wistar Rats
• Unveiling the Antimicrobial Potential of Homoeopathic Sarcode and Bowel Nosode: A Study on Histaminum and Dysenteriae Co against Escherichia Coli And Klebsiella Bacteria
• Incidence of Cardiovascular Events in Patients Receiving Hematopoietic Stem Cell Transplant (HSCT) in HCTM – (A Retrospective Cohort Study)
• A Prospective Case Study Examining the Effectiveness of Homoeopathic Medicine in Treating Degenerative Changes in the Lumbar Spine-A Case Report